Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of peginterferon lambda 1-a-treated chronic hepatitis C subjects
NL-OMON40600Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peginterferon lambda-1a in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: Durability of virologic response. Started May 2014; status: active, not recruiting.
02
Drugs
peginterferon lambda-1a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON40600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40600.